Moderna

Visit at https://www.modernatx.com/en-US

Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. The company's mission is to deliver the greatest possible impact to people through mRNA medicines.

Positive signals

Moderna's ESG profile demonstrates a positive impact on job creation (+1.95) and societal infrastructure (+0.26), according to MarketBeat's 2025 ESG impact assessment.

Source →

Moderna's management of ESG material risks is rated as 'Strong' by Sustainalytics, highlighting robust ESG programs, practices, and policies relative to industry standards.

Source →

Moderna's net impact profile shows a significant positive contribution to health, with a +18.07 score in the 'Health' category, reflecting its impact on combating physical diseases and improving public health outcomes.

Source →

S&P Global included Moderna in its 2025 Sustainability Yearbook, recognizing the company among the top-performing companies globally for ESG practices based on the S&P Global Corporate Sustainability Assessment.

Source →

Moderna received a 'Low' ESG Risk Rating of 19.2 from Sustainalytics in November 2024, ranking 68th out of 843 companies in its industry, indicating strong management of ESG material risks compared to peers.

Source →

Concerns

Financial performance and revenue generation

MEDIUM

Source →

Patent infringement lawsuit regarding COVID-19 vaccine technology

HIGH

Source →

Moderna's net impact profile indicates a negative environmental score of -2.75, with greenhouse gas emissions contributing -1.43 to the overall score, reflecting ongoing challenges in reducing its environmental footprint.

MEDIUM

Source →

Despite strong ESG management, Moderna's exposure to material ESG risks is rated as 'Medium' by Sustainalytics, indicating that the company still faces notable industry-specific risks that require ongoing mitigation.

MEDIUM

Source →

Moderna's net impact profile shows a negative score for scarce human capital (-2.27), suggesting challenges in talent retention or workforce development relative to industry benchmarks.

MEDIUM

Source →

Moderna

Positive signals

Moderna's ESG profile demonstrates a positive impact on job creation (+1.95) and societal infrastructure (+0.26), according to MarketBeat's 2025 ESG impact assessment.

Moderna's management of ESG material risks is rated as 'Strong' by Sustainalytics, highlighting robust ESG programs, practices, and policies relative to industry standards.

Moderna's net impact profile shows a significant positive contribution to health, with a +18.07 score in the 'Health' category, reflecting its impact on combating physical diseases and improving public health outcomes.

S&P Global included Moderna in its 2025 Sustainability Yearbook, recognizing the company among the top-performing companies globally for ESG practices based on the S&P Global Corporate Sustainability Assessment.

Moderna received a 'Low' ESG Risk Rating of 19.2 from Sustainalytics in November 2024, ranking 68th out of 843 companies in its industry, indicating strong management of ESG material risks compared to peers.

Concerns

Financial performance and revenue generation

Patent infringement lawsuit regarding COVID-19 vaccine technology

Moderna's net impact profile indicates a negative environmental score of -2.75, with greenhouse gas emissions contributing -1.43 to the overall score, reflecting ongoing challenges in reducing its environmental footprint.

Despite strong ESG management, Moderna's exposure to material ESG risks is rated as 'Medium' by Sustainalytics, indicating that the company still faces notable industry-specific risks that require ongoing mitigation.

Moderna's net impact profile shows a negative score for scarce human capital (-2.27), suggesting challenges in talent retention or workforce development relative to industry benchmarks.

Alternatives